Stockscreener 앱 받기
22.12
9.53%
-2.33
시간 외 거래:
22.11
-0.01
-0.05%
전일 마감가:
$24.45
열려 있는:
$24.5
하루 거래량:
115.21K
Relative Volume:
1.11
시가총액:
$320.21M
수익:
$1.80M
순이익/손실:
$1.76B
주가수익비율:
0.1864
EPS:
118.674
순현금흐름:
$-149.23M
1주 성능:
-3.66%
1개월 성능:
+48.16%
6개월 성능:
+55.88%
1년 성능:
+71.74%
1일 변동 폭
$22.10
$24.75
1주일 범위
$22.10
$24.75
52주 변동 폭
$10.80
$24.75
인히브릭스 Stock (INBX) Company Profile
명칭
Inhibrx Biosciences Inc
전화
(858) 795-4220
주소
11025 N. TORREY PINES ROAD, SUITE 140, LA JOLLA
INBX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INBX
Inhibrx Biosciences Inc
|
22.12 | 332.37M | 1.80M | 1.76B | -149.23M | 118.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
인히브릭스 Stock (INBX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | JMP Securities | Mkt Perform |
| 2024-01-23 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2022-03-16 | 개시 | SMBC Nikko | Outperform |
| 2021-09-21 | 개시 | JMP Securities | Mkt Outperform |
| 2021-04-26 | 재개 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Credit Suisse | Outperform |
| 2020-09-14 | 개시 | Evercore ISI | Outperform |
모두보기
인히브릭스 주식(INBX)의 최신 뉴스
Inhibrx Biosciences Inc. Stock Analysis and ForecastGame-changing returns - jammulinksnews.com
Top Stocks for Hedge Fund Investments Elite Trader Market TipsBreakthrough profit margins - PrintWeekIndia
What drives Inhibrx Biosciences Inc. stock priceFree High-Return Strategy Alerts - PrintWeekIndia
What analysts say about Inhibrx Biosciences Inc. stockOverwhelming financial success - Jammu Links News
Is Inhibrx Biosciences Inc. a good long term investmentRecord-setting profit potential - jammulinksnews.com
What drives SERV stock priceHigh-performance investment picks - jammulinksnews.com
What drives PLAB stock priceExceptional stock performance - jammulinksnews.com
Inhibrx Biosciences: Seeing Soon If The Momentum Is Just Hype - Seeking Alpha
What makes Inhibrx Biosciences Inc. stock price move sharplyROI Driven Alerts - Newser
Why Inhibrx Biosciences Inc. stock attracts strong analyst attentionFree Exclusive Stock Market Insights - Newser
How Inhibrx Biosciences Inc. stock performs during market volatilitySmall Risk Large Return Trades - Newser
(INBX) Trading Signals - news.stocktradersdaily.com
Why INBX Is A Stock To Watch In 2025 - RTTNews
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell Microcap Growth Index - MarketScreener
How To Trade (INBX) - news.stocktradersdaily.com
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 2000 Defensive Index - MarketScreener
Inhibrx Biosciences Concludes 2025 Annual Stockholders Meeting - TipRanks
Inhibrx Reports First Quarter 2025 Financial Results - BioSpace
Inhibrx Slashes Q1 Losses by 45%, Reveals Multiple Clinical Trial Readouts Coming in 2025 - Stock Titan
Oropharyngeal Cancer Treatment Market Size in 7MM is expected - openPR.com
Larynx Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - openPR.com
Oropharyngeal Cancer Treatment Market Size in 7MM is expected to grow at a decent CAGR by 2032, estimates DelveInsight - Barchart.com
When the Price of (INBX) Talks, People Listen - news.stocktradersdaily.com
(INBX) On The My Stocks Page - news.stocktradersdaily.com
Change at the top for Phathom as Basta replaces Curran - BioCentury
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President By Investing.com - Investing.com South Africa
Inhibrx Biosciences reshuffles leadership, appoints new CSO and President - Investing.com India
Inhibrx Biosciences Announces Departure Of CSO And Appointments Of New CSO And President - TradingView
Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President - PR Newswire
How the (INBX) price action is used to our Advantage - news.stocktradersdaily.com
JMP maintains Market Perform on Inhibrx stock post-earnings - Investing.com India
Inhibrx Reports Fourth Quarter and Fiscal Year 2024 Financial Results - The Malaysian Reserve
Inhibrx Biosciences, Inc. SEC 10-K Report - TradingView
Inhibrx Acquisition: Key Details, Impact, and What Comes Next - sunsethq.com
Long Term Trading Analysis for (INBX) - Stock Traders Daily
Stocks Rebound as US Government Shutdown Seems Averted - The Globe and Mail
When (INBX) Moves Investors should Listen - Stock Traders Daily
Simpson Thacher Adds Partner From Wilson Sonsini - Law360
A closer look at Inhibrx Biosciences Inc (INBX)’s stock price trends - US Post News
BlackRock, Inc. Increases Stake in Inhibrx Biosciences Inc. - GuruFocus.com
Inhibrx reports promising ozekibart trial results - MSN
Inhibrx's SWOT analysis: oncology biotech stock faces pivotal year ahead - MSN
인히브릭스 (INBX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):